ABSTRACT OKT3 monoclonal antibody to human T cells inhibits the target cell lysis mediated by allogeneic cytotoxic T cells and the generation of these effector cells in mixed lymphocyte culture. This marked inhibition of cell-mediated lysis is not found with other monoclonal antibodies also reactive with cell surface antigens of human T cells (OKT1, OKT4, OKT5, OKT6, OKT8, and OKT11). OKT3 antibody is mitogenic and this effect appears to require receptor activation in that it occurs at low concentrations (10-12 M range) of OKT3 antibody, requires intact OKT3 IgG, and is inhibited by a factor(s) in human plasma. By contrast, the inhibition of allogeneic cell-mediated lysis by OKT3 antibody appears to be due to steric hindrance in that it requires higher concentrations of OKT3 antibody (10-8 M range), Fab fragments retain approximately 10% activity, and inhibition is demonstrable in the presence of human plasma. These findings are consistent with the suggestion that OKT3 antibody reacts with the human Tcell antigen-recognition structure.
An understanding of how specific precursor T cells and functionally mature effector T cells react with soluble or cell surface antigens and regulatory molecules or cells of the immune system has been a central issue in contemporary immunology. In particular, the nature of the T-cell receptor for antigen has proved elusive, although studies of anti-idiotypic antibodies have suggested some relationship to the antigen-recognition regions of immunoglobulins (1, 2) . Binding of antigens or antiidiotypic antibodies to T-cell receptors induces the proliferation (clonal expansion) of the specifically reactive T cell (3, 4) . Sim- ilarly, at subnanomolar concentrations, OKT3 monoclonal antibody to human T cells induces proliferation of peripheral T cells (5) , and this mitogenic property is not found with a number of other monoclonal antibodies reactive to the antigens of human T cells (5) . This selective and highly potent mitogenicity of OKT3 antibody raises the possibility that the antigenic structure with which OKT3 antibody reacts may be the antigen-recognition structure-either the receptor itself or molecules functionally or physically associated with the receptor. If this hypothesis were correct, the mitogenic effect of OKT3 antibody would be attributable to perturbation of the receptor and would thus mimic mitogenesis induced by antigens or anti-idiotypic antibodies.
We tested this hypothesis by studying the effect of OKT3 antibody in vitro in a system involving antigen recognition by T cells. T-cell reactions with soluble antigens or anti-idiotypic antibodies have been well studied in murine systems (1-4), but have not been so well-characterized in human systems. Therefore, we chose to study allogeneic cytotoxic T lymphocyte (CTL)-mediated cell lysis and the in vitro generation of CTLs after allogeneic stimulation. Both of these processes involve the recognition and binding of allogeneic antigens by the antigen receptors of precursor or functional CTLs (6) (7) (8) RPMI-1640 (GIBCO) supplemented with 20% pooled human plasma (prepared in our laboratory), 2 mM glutamine, penicillin (100 units/ ml) and streptomycin (100 /ug/ml) (GIBCO), 10 mM Hepes (GIBCO), and 50 p.M 2-mercaptoethanol.
Generation of CTLs. Mononuclear cells (1 x 107) and 1 X 105 mitomycin C-treated 799CP71 cells (responder/stimulator cell ratio, 100:1) were incubated in 5 ml of medium (RPMI-1640 supplemented with 20% heat-inactivated autologous plasma, glutamine, penicillin, streptomycin, 2-mercaptoethanol, and Hepes) in upright culture flasks (no. 3013, Falcon) maintained in a 95% air/5% CO2 atmosphere for 6 days at 37°C. After 2 and 4 days of culture, 2.5 ml of fresh medium was added to the flasks. For mitomycin C treatment, 799CP71 cells-were incubated at 1 x 107/ml with mitomycin C (50 ,ug/ml) for 30 min at 37°C. Normal mononuclear cells were also used as stimulator cells in MLC. Culturing procedure and mitomycin C treatment were the same as with 799CP71 tumor cells except that 1 X 107 stimulator cells were used (responder/stimulator cell ratio, 1:1).
Assay for CTL-Mediated Cytolysis. The procedure was as described (9) . 799CP71-cells were used as target cells; they were labeled with Na251Cr 04 (New England Nuclear). Cells (1 X 107) were incubated in 0.5 ml of medium containing 250 ,uCi (1 Ci = 3.7 X 10'0 becquerels) of 5"Cr for 60 min at 37C. In the cytotoxicity assays, 1 x 104 target cells were mixed with effector cells at desired ratios in a total volume of 200 ,ul of medium in round-bottom wells of microtiter plates (Linbro Division, Flow Laboratories, Hamden, CT) and were incubated at 37°C for 4 hr. The medium contained 10% pooled human plasma unless otherwise specified; The 5"Cr released to the medium by the Abbreviations: CTL, cytotoxic T lymphocyte; MLC, mixed lymphocyte culture; CML, cell-mediate-d lysis.
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lysed target cells was determined in a gamma scintillation counter. Percent specific release was defined as 100 (ER-SR)/ (MR-SR), in which ER (experimental release) and SR (spontaneous release) were 51Cr released in the presence and absence, respectively, of immune effector cells and MR (maximal release) was 5"Cr released from target cells after they were frozen and thawed three times.
OKT3-Induced Mitogenesis. Mononuclear cells (2 x 105) were incubated with serially diluted OKT3 antibody in a total volume of 200 /.l of medium in flat-bottom wells of microtiter plates (Linbro). The medium contained 10% fetal calf serum or autologous plasma as specified. After approximately 65 hr of culture at 370C, 0.5 ,uCi of [3H]thymidine (New England Nuclear) in 10 ,u1 of medium was added to the wells and the cultures were incubated for an additional 6 hr. Cells were harvested and washed by using an automatic cell harvester. The incorporated 3H trapped in the filter was determined by using liquid scintillation counting.
Monoclonal Antibodies to Human T Cells. Hybridoma lines were produced and maintained as described (10, 11) . The seven monoclonal antibodies included in the present studies were (a) OKT1, OKT3, and OKT1L, all of which react with all peripheral T cells (5, 12, 13) ; (b) OKT4, which reacts with the helper/inducer subset of T cells (14); (c) OKT5 and OKT8, which react with suppressor/cytotoxic subset of T cells (15) ; and (d) OKT6, which reacts only with thymocytes (12, 13, 15) . The ascitic fluids of the hybridoma-bearing mice contained 1-5 mg of specific monoclonal antibodies per ml (10) . For several monoclonal antibodies, the IgG fraction in the ascitic fluids was isolated by Sephacryl S-200 gel chromatography. Antibody concentration was calculated from absorbance at 278 nm: 1.5 units (1 cm light pass) were equivalent to 1.0 mg of IgG per ml.
Fab Fragment of OKT3 Antibody. Purified OKT3 antibody (IgG2), 30 mg in 20 ml of 0.1 M sodium phosphate, pH 7.0/ 10 mM cysteine/2 mM EDTA, was mixed with 0.3 mg of papain (Millipore, Freehold, NJ) and incubated at 37°C for 16 hr. The digest was dialyzed against phosphate-buffered saline three times. The insoluble precipitate was removed by centrifugation and the volume of the supernatant was adjusted to 30 ml. A 6-ml sample of the supernatant was absorbed with 0.5 ml of protein A-conjugated Sepharose CL4B (Pharmacia) four times to remove Fc fragments and the residual undigested OKT3 antibody molecules. The amount of protein A in each absorption (in 0.5 ml of resin) had the capacity to bind 10 mg of IgG. Sodium dodecyl sulfate/polyacrylamide gel electrophoretic analysis of the Fab fragments revealed no detectable intact IgG molecules even prior to absorption with protein A.
RESULTS
Most experiments involved adding monoclonal antibodies to alloreactive CTLs that had been generated in MLC just prior to evaluation of their cytotoxicity in a 4-hr 5"Cr-release assay.
From preliminary experiments an effector-to-target cell ratio of 50 was chosen because the release of 51Cr from lysed target cells was approaching maximal at this ratio and higher ratios would therefore have an excess of effector cells.
OKT3 antibody caused more than 90% inhibition of specific cell lysis (Figs. 1 and 2 ) and this inhibition was half maximal at an OKT3 antibody concentration of approximately 500 ng/ml. The cytotoxic activity of CTLs generated in MLC with allogeneic mononuclear cells as stimulator cells was also blocked by OKT3 antibody (data not shown). By contrast, other monoclonal antibodies reactive with surface antigens of human T cells did not produce such striking inhibition. OKT5 and OKT8 antibodies, both of which react with a cytotoxic/suppressor subset 
of T cells, caused slight inhibition (20-30%).
Higher concentrations of these two antibodies did not inhibit to a greater extent (Fig. 1) . No inhibition was obtained with OKT1 and OKT11 antibodies which react, like OKT3 antibody, with antigens on all peripheral T cells (10, 13) .
The inhibitory effect of OKT3 antibody on allogeneic CML occurred whether fetal calf serum or human plasma was used in the assay (Fig. 2) .
Purified Fab fragments of OKT3 antibody (OKT3 Fab) were also inhibitory to allogeneic CMLs, although they appeared to have only 10% of the activity of intact OKT3 antibody (OKT3 IgG) (Fig. 3) .
The its effects on the inhibition of allogeneic CML. First, OKT3 antibody was maximally mitogenic at 1 ng/ml with 50% maximal mitogenesis at 50 pg/ml (0.3 pM) (Fig. 4) ; by contrast, 500 ng of OKT3 antibody per ml (3 nM) was needed for 50% maximal inhibition of allogeneic CML. Second, human plasma was inhibitory for OKT3-induced mitogenesis (human serum had identical effects), whereas human plasma did not affect OKT3 antibody inhibition of allogeneic CML. Third, Fab fragments of OKT3 showed negligible mitogenicity, having less than 1000-fold potency and a maximal effect of approximately 30%; by contrast, OKT3 Fab retained 10% inhibitory activity for allogeneic CML.
The inhibitory effect of OKT3 antibody on allogeneic CML was not restricted to the effector phase. OKT3 antibody added at or 20 hr after the initiation of MLC also resulted in inhibition of allogeneic CML (Fig. 5) . DISCUSSION The progressive maturational and functional stages of T-cell differentiation can be distinguished by the presence of various cell surface differentiation antigens (16) (17) (18) . In the mouse these have been identified in general with alloantisera (16) (17) (18) (19) (10, 11, 20, 21) . Little is known of the functional roles of cell surface antigens. Antisera against murine Lyt 2 and 3 antigens, which are present on the cytotoxic/suppressor T-cell subset (17) were found to inhibit T-cell mediated lysis, suggesting that the Lyt 2 or 3 antigens may be associated with the cytolytic apparatus (22, 23) .
We have generated a series of monoclonal antibodies reactive with human thymocytes or peripheral T cells (the OKT series OKT1, -3, -4, -5, -6, -8, and -11) (10, 11 Immunology: Chang et aL tion of receptors suffices to transmit the signal (26) ; this would be equivalent to the mitogenic action of OKT3 antibody at low concentrations. If OKT3 antibody blocked the T-cell antigen recognition by binding to the antigen recognition structure, one could envision higher concentrations being required to achieve complete receptor occupancy. Another distinguishing feature was inhibition of OKT3 antibody-induced mitogenesis by human plasma (or serum) which did not affect OKT3 antibody inhibition of allogeneic CML. Presumably, the inhibitory factor(s) in human plasma affect mitogenesis at a postreceptor level.
The finding that OKT3 antibody inhibits allogeneic CML at both the level of effector cells and the precursor cells suggests a practical utility of this antibody in clinical immunosuppression. Heterologous anti-human lymphocyte or thymocyte antisera have been used successfully for immunosuppression in human organ transplantation and most researchers have concluded that they are effective by virtue of elimination of T cells by complement-mediated lysis (27, 28) . One impediment to the indiscriminate use of heterologous antithymocyte globulin has been the difficulty of standardizing batches and the problem of adequate absorption to remove reactivity with antigens on cells other than T cells. OKT3 antibody would seem to offer the potential for production of a highly purified molecule capable of causing rapid immunosuppression by direct interaction with the putative antigen recognition structure of human T cells.
